Clinical trials: Moderate Active Ulcerative Colitis
Colitis, Ulcerative
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- PURSUIT 2 (NCT03596645)
- Testing
- Golimumab, Infliximab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
- Trial name
- ELEVATE UC 52 (NCT03945188)
- Testing
- Etrasimod
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 433 people
- Sponsor
- Arena Pharmaceuticals
Ulcerative Colitis
Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
The purpose of this study is to evaluate the safety and efficacy of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), compared with placebo.
- Trial name
- NCT00659802
- Testing
- HMPL-004 low dose, HMPL-004 high dose
- Volunteers
- 224 people
- Sponsor
- Hutchison Medipharma Limited
Ulcerative Colitis
Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients
This study is designed as a proof of concept of KRP203 for induction of remission in ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory…
- Trial name
- NCT01375179
- Testing
- KRP203
- Where
- 14 sites in Belgium, Germany and 4 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Inflammatory Bowel Disease, Ulcerative Colitis
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
To establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after…
- Trial name
- NCT00408174
- Testing
- Balsalazide disodium
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Trial name
- EMERALD-3 (NCT07415044)
- Testing
- LY4268989
- Where
- 258 sites in United States, Argentina and 26 more
- Volunteers
- 1,431 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis (UC)
Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis
The purpose of this protocol is to evaluate the safety and efficacy of Alpha-0261 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT07744646
- Testing
- Alpha-0261
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- SHINE-2 (NCT05784246)
- Testing
- Mirikizumab IV, Mirikizumab SC
- Where
- 34 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis
Combination Therapy with Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative colitis: A Single Blinded, International Randomized Controlled Trial
- Trial name
- INDUCT (NCT03980405)
- Testing
- Group 1- Control Diet, Group 2- UCD Diet
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Prof. Arie Levine
Ulcerative Colitis
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active…
- Trial name
- NCT03093259
- Testing
- ABX464
- Where
- 19 sites in Austria, Belgium and 6 more
- Volunteers
- 32 people
- Sponsor
- Abivax S.A.
Ulcerative Colitis
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis
The overall objective of this study is to assess the safety and efficacy of high dose and low dose Asacol administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks to children and adolescents with…
- Trial name
- NCT00713310
- Testing
- Asacol 400 mg
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 83 people
- Sponsor
- Warner Chilcott
Moderate to Severe Ulcerative Colitis
A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis
The study is being conducted to evaluate the safety, tolerability and pharmakokinetics of HRS-7085 in adults.
- Trial name
- NCT07760831
- Testing
- HRS-7085 tablets
- Where
- Moldova
- Volunteers
- 8 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ulcerative Colitis
An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)
This is a randomised, double-blind, placebo-controlled study to assess the safety and tolerability of multiple ascending doses of BT051 in subjects with moderately to severely active ulcerative colitis.
- Trial name
- SCOUT (NCT05084261)
- Testing
- BT051 200 mg, BT051 800 mg, BT051 3200 mg
- Where
- 6 sites in United States, Georgia and 2 more
- Volunteers
- 24 people
- Sponsor
- Adiso Therapeutics